Tuesday , November 21 2017
Home / Conditions / Type 1 Diabetes / ADA/JDRF Type 1 Diabetes Sourcebook, Excerpt #15: Beta-Cell Replacement Therapy, Part 2 of 2

ADA/JDRF Type 1 Diabetes Sourcebook, Excerpt #15: Beta-Cell Replacement Therapy, Part 2 of 2

Anne Peters, MD, and Lori Laffel, MD, MPH, Editors
Jane Lee Chiang, MD, Managing Editor

ADA-JDRF-Type-1-Diabetes-Sourcebook-image

Andrew M. Posselt, MD, PhD, FACS, and Peter Stock, MD, PhD

Follow this link for Part 1: Beta-Cell Replacement

(See also our recent interview on the use of pig islets in Phase 3 trials with Dr. Eli Lewis.)

The importance of the immune response in islet cell transplants was made evident by the vastly improved outcomes in patients undergoing autotransplantation versus allotransplantation. In addition to the allogeneic immune response, patients with T1D also have an autoimmune destruction of their native beta-cells as the etiology of their disease. This autoimmune response needs to be suppressed if the transplanted beta-cells are to survive. In 2000, the group at the University of Alberta reported consistent insulin independence using a strategy that is now known as the Edmonton protocol.27 This protocol consisted of infusing at least 8,000-9,000 islet equivalents (IEQs) per kilogram of body weight (this usually required two to three separate infusions). A normal-size pancreas has an estimated ~1 million islets. It is thought that stable independence needs ~8,000-9,000 IEQs (essentially islets), so a 70-kg person needs ~600,000-700,000 islets, which represents an extremely good yield from a single pancreas.35 However, although more is better, islet number is not the only factor….

The Edmonton protocol also included an immunosuppressive regimen that avoided steroids and minimized calcineurin inhibitors, both toxic to beta-cells. An antibody against the interleukin-2 receptor (daclizumab) was used for induction therapy, and sirolimus and low-dose tacrolimus were used for long-term immunosuppression. Using these techniques, researchers were able to achieve insulin independence in seven patients.27,36

DCMS162CG1

These results set off a new wave of interest in islet cell transplantation, and multiple other centers in the U.S. and worldwide began to perform islet transplants (Fig. 4.4).37 A 2007 report from the Collaborative Islet Transplant Registry showed that 28 centers in the U.S. were currently or had been active in islet transplantation and that 783 patients had received this treatment. In addition, ~65% of patients were able to achieve insulin independence, and 24% were still free of the need for insulin at three years time.38 This improvement in results has continued. The most recent report from the Collaborative Islet Transplant Registry (CITR; 2011) showed insulin independence rates of ~45% at three years.39

Hypoglycemia Unawareness

Hypoglycemic unawareness in islet transplant recipients decreased from 60% pretransplant to 4% at three years post-transplant, even in patients who returned to insulin use. One possible explanation for this result is that nearly 80% of patients did retain some graft function, as defined by the presence of C-peptide at three years, which helped control glucose regulation, even if exogenous insulin use was resumed.40,41 More recently, the National Institutes of Health (NIH) have supported an ongoing, multicenter trial of clinical islet transplantation that is designed to serve as a stepping stone for standardization of islet isolation and transplantation, and to provide data that can be used to support efforts to make islet transplantation a U.S. Food and Drug Administration (FDA)-approved procedure (see http://www.citisletstudy.org).

Adverse Events

Adverse events were noted that related to infusion of the islets into the portal vein, such as elevation in liver enzymes, bleeding, and portal vein thrombosis, but these were well tolerated.42,43 More serious consequences included the development of neoplasms that were likely related to immunosuppression, a death from viral meningitis, and development of antidonor alloantibodies when immunosuppressive drugs were discontinued. Such sensitization was concerning because it could place patients at increased risk for rejection in the future and also limit the pool of acceptable donors for future islets or kidneys.44,45

PATIENT SELECTION FOR PANCREAS VERSUS PANCREATIC ISLET TRANSPLANTATION

Although solid organ pancreas transplantation has been the gold standard for the achievement of long-term insulin independence, recent advances in islet transplantation have made cellular transplants an increasingly attractive alternative for beta-cell replacement. In fact, some studies using more aggressive immunosuppression with lymphodepletion as induction therapy have demonstrated five-year insulin independence rates in greater than 50% of islet recipients. These results are now approximating those seen with PTA.

At this point, islet transplants remain in the domain of experimental trials and rarely are covered by insurance. Islet transplants after kidney transplants are covered by Medicare, and if they are part of an NIH-sponsored trial, islet transplants alone are also covered by Medicare. At this time, other insurance companies do not cover islet transplants. Islet transplantation, however, likely will become an FDA-approved procedure in the near future. By the time it is approved, the algorithm by which beta-cell replacement therapy is offered to a given patient will change. Until this change, any patient with T1D who is a candidate for pancreas transplantation (SPK, PAK, or PTA) and has a cardiovascular system that can tolerate whole organ pancreas transplantation should be offered that procedure. For patients with advanced cardiovascular disease or patients who do not wish to or cannot undergo an open surgical procedure, islet transplantation can be offered but only as part of an experimental trial (see citisletstudy.org, niddk.nih.gov, and clinicaltrials.gov). Until islet transplantations can be offered routinely as a covered service, the algorithm of who should be offered an islet versus pancreas transplant will depend on the state of the art of islet transplantation available at the time. Currently, patients who are highly sensitized or have high insulin requirements remain better candidates for solid organ pancreas transplants.

CONCLUSION

Pancreas transplantation is a safe and durable strategy to achieve insulin independence in patients with T1D. Long-term insulin independence can be achieved as well as stabilization of the devastating secondary complications of long-standing diabetes. Rigorous immune monitoring combined with aggressive immunosuppression have resulted in excellent outcomes, even in PTA recipients who remain at an increased risk for acute rejection. Nonetheless, the number of patients who can benefit from this procedure is limited by the surgical and cardiovascular stresses associated with solid organ pancreas transplantation. Although islet transplantation remains an experimental procedure, progress continues in long-term success utilizing aggressive immunosuppression protocols. Further improvements in islet isolation, immunosuppression, and new sources of beta-cells derived from stem cells will move islet transplantation into the realm of FDA-approved procedures within the next few years. Upon approval, the number of options available for beta-cell replacement will increase and potentially benefit more patients with T1D who currently are not candidates for beta-cell replacement via whole organ pancreas transplantation. These would include patients who are too old or have significant medical comorbidities, such as heart disease, that would put them at higher risk for perioperative complications.

Significant advances in the technology of islet isolation, as well as improvements in the ability to protect transplanted islets from both the alloimmune and autoimmune responses, have led to major improvements in long-term rates of insulin independence. The logistics of isolating sufficient islets from a limited pool of donors remains a major limiting factor for widespread application as a treatment for diabetes. Potential solutions for new sources include xenogeneic tissue, embyonic stem cells (ES) differentiated into insulin-producing cells, and induced pluripotent stem cells (iPS) cells.46,47

Although clinical trials using porcine islets likely will move forward in the near future, success will require novel immunosuppressive strategies to over-come the potent xenogeneic response. In addition, concerns persist regarding the risk of transmitting infectious diseases from one species to another. Although iPS-derived beta-cells have the promise of providing a source of human leukocyte antigen (HLA)–matched beta-cells for the diabetic patient, this technology has not evolved as far as the ES-derived beta-cell.48

The first clinical trials of ES-derived beta-cells will likely be moving forward in the near future. Several teams have produced insulin-producing beta-cells derived from human ES lines by culturing the cells with selected differentiation factors. These cells have been capable of reversing diabetes in immunodeficient mice. As these ES-derived beta-cells move closer to clinical trials, they will still require protection from both the alloimmune and autoimmune responses, as they express HLA derived from the ES cell line.49–51 Strategies that are being considered include the immunosuppressive regimens found to be effective in the human islet trials as well as use of an immunoisolation barrier.52 The latter strategy also will provide a barrier for undifferentiated cells, which could develop from the pluripotent ES cell line. Current platforms and immunosuppressive strategies that are successful for islet allotransplantation will form the basis for the first clinical trials for ES-derived beta-cells. The potential for an unlimited source of beta-cells undeniably will have a profound impact on the treatment of T1D.

GAPS ACCORDING TO THE EDITORS

1. There is a need for the identification of additional sources of beta-cells for replacement, either from donor organs, iPS cells, ES cells, or other options, with additional investigations aimed at improved isolation, purification, and differentiation processes.

2. There is a need for beta-cell replacement approaches that limit or reduce exposure to toxic immunosuppressive therapies.

3. Although many of the issues related to optimizing islet replacement therapy remain within the realm of research, there is a need to ensure rapid insurance reimbursement for effective treatments, such as islet transplantation.

REFERENCES

1. Group TDCaCTR: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group.N Engl J Med 329:977–986, 1993

2. Gruessner AC, Sutherland DE: Report for the international pancreas trans-plant registry, 2000. Transplant Proc33:1643–1646, 2001

3. Sutherland DE, Gruessner RW, Gruessner AC: Pancreas transplantation for treatment of diabetes mellitus. World J Surg25:487–496, 2001

4. Feng S, Barr M, Roberts J, Oberbauer R, Kaplan B: Developments in clini-cal islet, liver thoracic, kidney and pancreas transplantation in the last 5 years. Am J Transplant 6:1759–1767, 2006

5. Sutherland DE, Gruessner RW, Dunn DL, et al.: Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg 233:463–501, 2001

6. Gruessner RW, Sutherland DE, Gruessner AC: Mortality assessment for pancreas transplants. Am J Transplant4:2018–2026, 2004

7. Fiorina P, Folli F, Zerbini G, et al.: Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol 14:2150–2158, 2003

8. Shapiro AM, Ricordi C, Hering BJ, et al.: International trial of the Edmon-ton protocol for islet transplantation. N Engl J Med 355:1318–1330, 2006

9. Rother KI, Harlan DM: Challenges facing islet transplantation for the treat-ment of type 1 diabetes mellitus. J Clin Invest 114:877–883, 2004

10. Cravedi P, van der Meer IM, Cattaneo S, Ruggenenti P, Remuzzi G: Suc-cesses and disappointments with clinical islet transplantation. Advances in Experimental Medicine and Biology 654:749–769, 2010

11. Sutherland DE, Goetz FC, Chinn PL, et al.: Clinical pancreas and islet transplantation. Part 2: pancreas transplantation at the University of Min-nesota. Primary Care 10:717–722, 1983

12. Sutherland DE, Moudry KC: Clinical pancreas and islet transplantation. Transplant Proc 19:113–120, 1987

13. Gruessner RW, Sutherland DE, Najarian JS, Dunn DL, Gruessner AC: Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus. Transplant 64:1572–1577, 1997

14. Gruessner RW, Sutherland DE, Parr E, Humar A, Gruessner AC: A pro-spective, randomized, open-label study of steroid withdrawal in pancreas transplantation—a preliminary report with 6-month follow-up. Transplant Proc33:1663–1664, 2001

15. Humar A, Ramcharan T, Kandaswamy R, et al.: Pancreas after kidney transplants. Am J Surg 182:155–161, 2001

16. Singh RP, Stratta RJ: Advances in immunosuppression for pancreas trans-plantation. Curr Opin Organ Transplant 13:79–84, 2008

17. Najarian JS, Gruessner AC, Drangsteveit MB, et al.: Insulin independence of more than 10 years after pancreas transplantation. Transplant Proc 30:1936– 1937, 1998

18. Sutherland DE: Pancreas and pancreas-kidney transplantation. Curr Opin Nephrol Hypertens 7:317–325, 1998

19. Gruessner AC, Sutherland DE, Gruessner RW: Pancreas transplantation in the United States: a review. Curr Opin Organ Transplant 15:93–101, 2010

20. Nathan DM: Isolated pancreas transplantation for type 1 diabetes: a doctor’s dilemma. JAMA 290:2861–2863, 2003

21. Ballinger WF, Lacy PE: Transplantation of intact pancreatic islets in rats. Surgery 72:175–186, 1972

22. Sutherland DE: Pancreas and islet transplantation. II. Clinical trials. Diabe-tologia 20:435–450, 1981

23. Bretzel RG, Brendel M, Eckhard M, et al.: Islet transplantation: present clinical situation and future aspects.Experimental and Clinical Endocrinology & Diabetes 109 (Suppl. 2):S384–S399, 2001

24. Blondet JJ, Carlson AM, Kobayashi T, et al.: The role of total pancreatec-tomy and islet autotransplantation for chronic pancreatitis. Surg Clin North Am 87:1477–1501, 2007

25. Sutherland DE, Radosevich DM, Bellin MD, et al.: Total pancreatec-tomy and islet autotransplantation for chronic pancreatitis. J Am Coll Surg 214:409–424, 2012; discussion 24-6

26. Bretzel RG: Current status and perspectives in clinical islet transplantation. J Hepatobiliary Pancreat Surg 7:370–373, 2000

27. Shapiro AM, Lakey JR, Ryan EA, et al.: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppres-sive regimen. New Engl J Med 343:230–238, 2000

28. Tsujimura T, Kuroda Y, Kin T, et al.: Human islet transplantation from pan-creases with prolonged cold ischemia using additional preservation by the two-layer (UW solution/perfluorochemical) cold-storage method. Trans-plantation74:1687–1691, 2002

29. Lakey JR, Burridge PW, Shapiro AM: Technical aspects of islet preparation and transplantation. Transplant Int16:613–632, 2003

30. Balamurugan AN, Breite AG, Anazawa T, et al.: Successful human islet isola-tion and transplantation indicating the importance of class 1 collagenase and collagen degradation activity assay. Transplantation 89:954–961

31. Anazawa T, Balamurugan AN, Bellin M, et al.: Human islet isolation for autologous transplantation: comparison of yield and function using SERVA/Nordmark versus Roche enzymes. Am J Transplant 9:2383–2391, 2009

32. Posselt AM, Szot GL, Frassetto LA, Masharani U, Stock PG: Clinical islet transplantation at the University of California, San Francisco. Clin Trans-plant, 235–243, 2010

33. Hering BJ, Kandaswamy R, Ansite JD, et al.: Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 293:830–835, 2005

34. Posselt AM, Szot GL, Frassetto LA, et al.: Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive pro-tocols based on T-cell adhesion or costimulation blockade. Transplantation90:1595–1601, 2010

35. Shapiro AM: State of the art of clinical islet transplantation and novel pro-tocols of immunosuppression. Current Diabetes Reports 11:345–354, 2011

36. Ryan EA, Lakey JR, Rajotte RV, et al.: Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 50:710–719, 2001

37. Ricordi C, Inverardi L, Kenyon NS, et al.: Requirements for success in clini-cal islet transplantation. Transplantation 79:1298–1300, 2005

38. 2007 update on allogeneic islet transplantation from the Collaborative Islet Transplant Registry (CITR). Cell Transplant 18:753–767, 2009

39. Seventh annual data report, 2011. Available at http://www.citregistry.org/ reports/reports.htm. Accessed 1 August 2012

40. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JRT, Shapiro AMJ: Five-year follow-up after clinical islet transplantation. Diabetes 54:2060–2069, 2005

41. Ryan EA, Shandro T, Green K, et al.: Assessment of the severity of hypo-glycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 53:955–962, 2004

42. Kawahara T, Kin T, Kashkoush S, et al.: Portal vein thrombosis is a poten-tially preventable complication in clinical islet transplantation. Am J Trans-plant 11:2700–2707, 2011

43. Rafael E, Ryan EA, Paty BW, et al.: Changes in liver enzymes after clinical islet transplantation. Transplantation 76:1280–1284, 2003

44. Chhabra P, Brayman KL: Current status of immunomodulatory and cel-lular therapies in preclinical and clinical islet transplantation. J Transplant, 637–692, 2011

45. Naziruddin B, Wease S, Stablein D, et al.: HLA class I sensitization in islet transplant recipients: report from the Collaborative Islet Transplant Registry. Cell Transplant 21:901–908, 2012

46. Miszta-Lane H, Mirbolooki M, James Shapiro AM, Lakey JR: Stem cell sources for clinical islet transplantation in type 1 diabetes: embryonic and adult stem cells. Med Hypoth 67:909–913, 2006

47. Bretzel RG, Eckhard M, Brendel MD: Pancreatic islet and stem cell trans-plantation: new strategies in cell therapy of diabetes mellitus. Panminerva Medica 46:25–42, 2004

48. Casu A, Trucco M, Pietropaolo M: A look to the future: prediction, preven-tion, and cure including islet transplantation and stem cell therapy. Pediatr Clin North Am 52:1779–1804

49. Kandeel F, Smith CV, Todorov I, Mullen Y: Advances in islet cell biology: from stem cell differentiation to clinical transplantation: conference report. Pancreas 27:e63–78, 2003

50. Dominguez-Bendala J, Inverardi L, Ricordi C: Stem cell-derived islet cells for transplantation. Curr Opin Organ Transplant, 2010

51. Duprez IR, Johansson U, Nilsson B, Korsgren O, Magnusson PU: Prepara-tory studies of composite mesenchymal stem cell islets for application in intraportal islet transplantation. Upsala J Med Sci 116:8–17, 2011

52. Vaithilingam V, Tuch BE: Islet transplantation and encapsulation: an update on recent developments. Rev Diabet Stud 8:51–67, 2011

Used with permission by the American Diabetes Association. Copyright © 2013 American Diabetes Association.

Please note: We are proud to have Dr. Anne Peters as a member of our Advisory Board member for Diabetes In Control, Inc.

 

T1-diabetes-sourcebookIf you would like to purchase the full text of The Type 1 Diabetes Sourcebook, Anne Peters, MD, and Lori Laffel, MD, MPH, editors, and Jane Lee Chiang, MD, managing editor, just follow this link.